Spryte Medical Reports Positive INSYTE Trial Results
The pivotal study of its nOCT Imaging System met its primary effectiveness endpoint in neurovascular procedures.
Updated on Nov. 19, 2026 in Healthcare

Spryte Medical announced positive results from the INSYTE pivotal trial of its nOCT Imaging System, the first FDA-approved pivotal trial of an intravascular optical coherence tomography system designed for the neurovasculature. The trial met its primary effectiveness endpoint, with no serious adverse events directly attributed to nOCT imaging.
Why it matters
The results suggest intravascular imaging could change how clinicians plan endovascular treatment of intracranial aneurysms, a procedure performed at medical centers across Massachusetts and elsewhere. The nOCT system remains investigational and is not commercially available in the United States.
The INSYTE pivotal trial produced diagnostic-quality images exceeding 50 mm, more than double the 24 mm target, and changed investigator treatment decisions in over 40% of patients in a prespecified analysis. Whether these decision changes translate into better patient outcomes has not yet been established, and follow-up continues at six months.
The players
Spryte Medical
Spryte Medical is a medical device company based in Bedford, Massachusetts, developing intravascular imaging technology for neurovascular procedures.
Ricardo Hanel
Ricardo Hanel is a neurointerventional physician at Jacksonville's medical institutions who served as co-principal investigator of the INSYTE trial and presented the results at the SVIN Annual Meeting in Las Vegas.
The details
The trial measured nOCT imaging during endovascular treatment of intracranial aneurysms, navigating the brain's blood vessels with standard neurointerventional techniques to capture micron-level images of vessel walls and treatment devices. Observed changes in treatment included device sizing, device selection, antiplatelet therapy administration, and angioplasty.
Timeline
The nOCT Imaging System received FDA Breakthrough Device Designation in 2024.
Spryte Medical announced the positive INSYTE results on November 19, 2026.
Patients enrolled in the trial will receive follow-up imaging at six months.
Industry Roadmap
The INSYTE trial extends intravascular optical coherence tomography, a technology long used to guide coronary stenting, into the far more delicate brain vasculature. It is the first FDA-approved pivotal trial of such a system designed for the neurovasculature, marking a step toward imaging standards in neurointerventional care.
The nOCT system is not commercially available in the United States, so the trial results do not change treatment options for patients today. If the device later reaches the market, clinicians could use its imaging to adjust sizing, device selection, and medication decisions during aneurysm treatment.
The takeaway
Intravascular imaging that reveals vessel-wall detail may shift treatment decisions during brain aneurysm procedures, but the benefit to patient outcomes still needs longer-term study. Patients and families should discuss current options with their neurointerventional team.
Further reading
For more on the regional medical device sector, see Healthcare coverage across Massachusetts.
Source note: This article includes information reported by The Manila times.






